MAPT and Alzheimer disease: Although high levels of tau oligomers in CSF have been well-incorporated into diagnostic workup of AD (224), tau oligomer measurements in PSP have not yet shown reliable and consistent pattern except for decreased level of total tau and phospho-tau compared to AD and healthy controls (225).